The ARASAFE study showed that a 50 mg/m2 biweekly docetaxel regimen reduced severe side effects compared to the standard 75 mg/m2 triweekly regimen in mHSPC patients. The experimental regimen resulted ...
A partitioned-survival lifetime model (2025 USD) compared ADT alone with seven intensification strategies across PFS, post-progression, and death, using published survival curves and literature-based ...
Please provide your email address to receive an email when new articles are posted on . Men with metastatic castration-resistant prostate cancer had significantly longer OS with docetaxel rechallenge ...
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis The standard of care for ...
orgovyx (relugolix) is a medicine used to treat advanced prostate cancer in adults. Advanced prostate cancer means that the cancer has spread outside of the prostate. Advanced cancers have often come ...
Dose optimisation and PSMA receptor intensification with 177Lu-PSMA-597 in metastatic castration-resistant prostate cancer (mCRPC): The randomised phase II OPTIMAL-PSMA trial. This is an ASCO Meeting ...
ASPIRE trial explores survival benefits of adding chemotherapy to standard prostate cancer treatment
The Alliance for Clinical Trials in Oncology is now enrolling patients in the ASPIRE trial (A032302)-a large-scale, phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results